| | eBook: Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Catalent’s Carla Vozone discusses the significant trends in the Orally Inhaled & Nasal Drug Delivery (OINDP) segment including larger molecules and novel indications. She also discusses changes within CDMOs and various challenges facing the industry. Learn more about trends in orally and nasally inhaled therapeutics, new avenues for existing dose forms, and industry response to OINDP trends. Download Now. |
|---|
Alpha Cognition's delayed-release Alzheimer's drug hits goal, teeing up approval filing Institut Pasteur, Satio ally to bring intradermal vaccine delivery to Africa Kelai pens Double Rainbow pact to pair drug delivery and biosynthesis tech Ex-Novartis unit Alcon keeps eye med expansion rolling with $770M pact to snap up Aerie After FDA rejection, Gilead's long-acting HIV med Sunlenca snags first global nod 'The Top Line': 2 deaths put Novartis' SMA gene therapy in the safety spotlight, what's behind AstraZeneca's next-gen CAR-T therapy tactics and more Featured Story | By Nick Paul Taylor Alpha Cognition has taken another step toward a filing for approval of its delayed-release treatment for Alzheimer’s disease, publishing top-line results from a study that compared the prospect to an incumbent product. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Institut Pasteur de Dakar has opened a new front in its push to enable low-cost access to vaccines, teaming up with the medtech company Satio to advance candidates based on intradermal delivery patch technology. read more By Nick Paul Taylor Kelai Pharmaceuticals has struck a deal to collaborate with Double Rainbow Biosciences, positioning it to explore the potential of biosynthetic therapeutics and the pairing of its drug delivery systems and its new partner’s capabilities. read more By Fraiser Kansteiner Former Novartis subsidiary Alcon, after targeting the pharmaceutical eye drop scene with a trio of recent drug purchases, is adding another pair of arrows to its ophthalmic quiver. And this time, the company is setting its sights long-distance. read more By Angus Liu Nearly six months after an FDA rejection, Gilead Sciences’ next-generation, long-acting HIV med lenacapavir has picked up its global-first approval in Europe. But the company still needs to find the first-in-class drug a proper combination partner after a high-profile Merck setback. read more By Teresa Carey This week on "The Top Line," we discuss Novartis’ gene therapy Zolgensma—and the two deaths following treatment. We also hear from AstraZeneca on its strategy to get into the CAR-T space with off-the-shelf cancer cell therapies. read more Resources Sponsored by: Ferma.AI, a Product of ZoomRx Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Catalent Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Thermo Fisher Scientific Set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Triangle Insights Group, LLC The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Events Promotional Review Committee Compliance and Best Practices Summit West (PRC West) September 20-22, 2022 | San Diego, CA Fierce New Product Planning Summit September 19-20, 2022 | Boston, MA Medical Affairs Strategic Summit West (MASS West) September 20-22, 2022 | San Diego, CA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Good Clinical Practice Summit (GCP): Part of the Fierce Clinical Collective October 24-26, 2022 | Philadelphia, PA | Presented by Fierce Pharma Clinical Quality Oversight Forum: Part of the Fierce Clinical Collective Oct 24-26, 2022 | Philadelphia PA | Presented by: Fierce Pharma Decentralized Clinical Trials Summit: Part of the Fierce Clinical Collective Oct 24-26, 2022 | Philadelphia, PA | Presented by: Fierce Pharma Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Drug Development Boot Camp® 2022 November 16-17, 2022 Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Free Virtual Event | 